

Substitute for form 1449/PTO (Revised 07/2005)		<div style="border: 1px solid black; border-radius: 50%; width: 100px; height: 100px; margin: 0 auto; display: flex; align-items: center; justify-content: center;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg);">O I P E</div> <div style="text-align: center;">JUL 10 2007</div> <div style="writing-mode: vertical-rl; transform: rotate(180deg);">OFFICE</div> </div>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/713,860
		Filing Date	11/17/03
		First Named Inventor	Wilson
		Group Art Unit	1614 1648
		Examiner Name	Hill, M. PARKIN, JEFFERY
Sheet 1 of 1		Attorney Docket Number	049542/284259

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
2	1	WO 99/64418	12-16-1999	NOVARTIS		
1	2	WO 99/21555	05-06-1999	TAKEDA CHEMICAL INDUSTRIES		
1	3	WO 01/74811 A2	10-11-2001	TAKEDA CHEMICAL INDUSTRIES		

OTHER DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	English Language Translation Attached
2	4	LAMBRECHT, G., "Design and Pharmacology of Selective H ₂ -Purinoceptor Antagonists," <i>Journal of Autonomic Pharmacology</i> , 1996, pp. 341-344, Vol. 16(6).	
2	5	LAMBRECHT, G., "Agonists and Antagonists Acting at P2X Receptors: Selectivity Profiles and Functional Implications," <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , 2000, pp. 340-350, Vol. 362.	

Examiner Signature	Date Considered
	09/30/2007

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.